DPX-Survivac and Pembrolizumab Trial
Phase 2
102
about 3.9 years
18+
17 sites in CA, FL, GA +8
About this study
Researchers are testing DPX-Survivac, pembrolizumab, with or without low-dose cyclophosphamide (CPA), in people with relapsed or refractory diffuse large B-cell lymphoma. The trial will last for about 1412 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take CPA
- 2.Take DPX-Survivac
- 3.Take Pembrolizumab
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Objective response rate (ORR) in each of the study arms
Secondary: Changes in Patient Reported Outcomes using the EQ-5D-5L Assessment, Changes in Patient Reported Outcomes using the FACT-Lym Assessment, Complete response (CR) rate in each of the study arms, Disease control rate (DCR) in each of the study arms, Duration of response (DOR) in each of the study arms, Progression-Free Survival in each of the study arms, Rate of Adverse Events using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 in each of the study arms
Oncology